<DOC>
	<DOCNO>NCT02775240</DOCNO>
	<brief_summary>The purpose study determine investigational treatment ( maribavir ) handle body administer two already approve drug ( digoxin dextromethorphan ) . The study also look safety tolerability maribavir coadministered digoxin dextromethorphan versus digoxin dextromethorphan alone .</brief_summary>
	<brief_title>Study SHP620 ( Maribavir ) Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<criteria>An understanding , ability , willingness fully comply study procedure restriction . Ability provide write , personally sign , date informed consent participate study , complete studyrelated procedure . Age 1850 year , inclusive time consent . Subjects must willing consent provide blood sample pharmacogenomics analysis . Willingness comply applicable contraceptive requirement protocol : 1 . Male , 2 . Female nonchildbearing potential 3 . Nonpregnant , nonlactating female 4 . Females must least 90 day postpartum nulliparous . Must consider `` healthy . '' Healthy status define absence evidence active chronic disease follow detailed medical surgical history , complete physical examination include vital sign , 12lead ECG , hematology , blood chemistry ( include T3 , T4 , TSH screen ) , urinalysis . Body mass index ( BMI ) 18.5 30.0 kg/m2 inclusive . Hemoglobin equal great 12.0g/dL . Ability swallow dose investigational product ( may multiple tablet one time consecutively 1 tablet time ) Subject clinically significant history disorder detect medical interview/physical examination cardiovascular , bronchopulmonary , gastrointestinal ( eg , inflammatory bowel disease , chronic diarrhea ) , hepatic , biliary ( include gallbladder removal ) , renal , hematological , endocrine , autoimmune , neurological , psychiatric disease ( include depression ) medical condition capable alter absorption , metabolism , elimination drug ; constitute risk factor take investigational product judgment investigator . Known suspect intolerance hypersensitivity investigational product ( ) , closely related compound , state ingredient . Significant illness , judge investigator , within 2 week first dose investigational product . Known history alcohol substance abuse within last year . Donation blood blood product ( eg , plasma platelet ) within 60 day prior receive first dose investigational product . Within 30 day prior first dose investigational product : 1 . Have use investigational product ( elimination halflife &lt; 6 day , otherwise 5 halflives ) . 2 . Have enrol clinical study ( include vaccine study ) , investigator 's opinion , may impact study . 3 . Have substantial change eat habit , assess investigator . Confirmed systolic blood pressure &gt; 139 mmHg &lt; 89 mmHg diastolic blood pressure &gt; 89 mmHg &lt; 49 mmHg . Twelvelead ECG demonstrate QTcB &gt; 450 msec screening . A positive screen alcohol drug abuse screen Day 1 , Period 1 . Male subject consume 21 unit alcohol per week 3 unit per day ; female subject consume 14 unit alcohol per week 2 unit per day ( 1 alcohol unit=1 beer 1 wine [ 5 oz/150 mL ] 1 liquor [ 1.5 oz/40 mL ] 0.75 oz alcohol ) . A positive human immunodeficiency virus , hepatitis B surface antibody , hepatitis C virus antibody screen . Use tobacco form ( eg , smoke chew ) nicotinecontaining product form ( eg , gum , patch ) . Exusers must report stop use tobacco least 30 day prior receive first dose investigational product . Routine consumption 2 unit caffeine per day subject experience caffeine withdrawal headache . ( One caffeine unit contain follow item : one 6 oz [ 180 mL ] cup coffee , two 12 oz [ 360 mL ] can cola , one 12 oz cup tea , three 1 oz [ 85 g ] chocolate bar . Decaffeinated coffee , tea , cola consider contain caffeine . ) Prior screen failure , randomization , participation , enrollment study prior enrollment clinical study investigate maribavir . Current use ( define use within 14 day prior first dose investigational product ) medication ( include overthecounter , herbal , homeopathic preparation [ eg , St. John 's wort , ginkgo biloba ] ) exception hormonal replacement therapy occasional use ibuprofen acetaminophen . History sensitivity heparin heparininduced thrombocytopenia . Ingestion know CYP3A modulators within 7 day Day 1 , Period 1 ( include grapefruit grapefruit juice , orange , Seville oranges , apple apple juice , vegetables mustard green family [ eg , kale , broccoli , watercress , collard green , kohlrabi , Brussels sprout , mustard ] , charbroiled meat , product contain ingredient ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Maribavir</keyword>
</DOC>